Revised */*/****

Shannon Celeste Kenney

McArdle Laboratory for Cancer Research

University of Wisconsin-Madison

**** ********** ******

Madison, WI 53706

Telephone: 608-***-**** (office)

Email: abph57@r.postjobfree.com

EDUCATION

College: Yale University

New Haven, Connecticut

September, 1972 - May, 1975

B.A. - Geology - awarded Magna Cum Laude

Medical School: Yale University School of Medicine

New Haven, Connecticut

September, 1975 - May, 1979

M.D. degree (Awarded as candidate for highest academic honors)

Residency: University of North Carolina Hospitals

Medicine/Pediatrics (4 year program)

July, 1979- June, 1983

Research Fellowship: Laboratory of Biology of Viruses

National Institute of Allergy and Infectious Diseases, NIH

July, 1983- June, 1985

Infectious Diseases

Fellowship: University of North Carolina Hospitals

July, 1985-July, 1987

EMPLOYMENT HISTORY

2006-present Wattawa Bascom Professor of Cancer Research, Department of Medicine and

Department of Oncology, University of Wisconsin School of Medicine and

Public Health

2004-2006 Sarah Graham Kenan Professor of Medicine and Microbiology & Immunology,

University of North Carolina School of Medicine, Chapel Hill, N.C.

1998-2006 Professor of Medicine (Division of Infectious Diseases) and Microbiology &

Immunology, University of North Carolina School of Medicine, Chapel Hill,

N.C.

1993-1998 Associate Professor (with tenure) of Medicine (Division of Infectious Diseases)

and Microbiology & Immunology, University of North Carolina School of

Medicine, Chapel Hill, N.C.

1987-1993 Assistant Professor of Medicine (Division of Infectious Diseases) and

Microbiology & Immunology, University of North Carolina School of

Medicine, Chapel Hill, N.C.

1987-2006 Research Scientist, Lineberger Comprehensive Cancer Center, University of

North Carolina School of Medicine, Chapel Hill, N.C.

CERTIFICATION/LICENSURE

National Board of Medical Examiners (Diplomat) (1979)

Board-certified in Internal Medicine (1983)

Board-certified in Pediatrics (1986)

Board-certified in Infectious Diseases (1990; recertified 2005)

Licensed to practice medicine in North Carolina and Wisconsin

PROFESSIONAL SOCIETIES

Fellow, Infectious Diseases Society of America

Member, American Society of Virology

Member, American Society for Clinical Investigation

Member, Association of American Physicians

Member, American Clinical and Climatological Association

Editorial Board, Journal of Virology

HONORS AND AWARDS

B.A. Awarded Magna Cum Laude

M.D. Degree Awarded Candidate for Highest Honors

Student Editor of Yale Journal of Biology and Medicine 1976-1979

Jefferson-Pilot Blake Newton Award, 1986

Jefferson-Pilot Fellowship in Academic Medicine, 1989-1991

NIH Research Career Development Award, 1992-1997

Elected to the American Society for Clinical Investigation, 1995

Ruth Hettleman Prize for Creativity in the Arts and Sciences, 1996

Member, NIH Study Section (AIDS-Related Research), 1996-2003

Member, IDSA Program Planning Committee, 1997-1999

Sarah Graham Kenan Professorship, 2004-2006

Board Member, International Epstein-Barr Virus Association, 2005-2010

2

Elected to the Association of American Physicians, 2005

Elected to the American Clinical and Climatological Association, 2005

Member, Burroughs Wellcome Fund s scientific Advisory Committee for the Clinical Scientists

Awards in Translational Research, 2005-present

Awarded Woodward Prize for best talk delivered at the American Clinical and Climatological

Association meeting, 2005

Wattawa Bascom Professor of Cancer Research, University of Wisconsin-Madison, 2006-present

Editorial Board, Journal of Virology

University of Wisconsin Department of Medicine Rankin Research Award, October 2007

GRANTS FUNDED (Active Support only)

Regulation of EBV Infection in Epithelial Cells

NIH/NCI R01 CA058853-18

a) PI Dr. Shannon Kenney

b) 20 percent effort

c) 5/4/2009 through 2/28/2014

d) $191,834 direct costs current year

EBV-based Strategies for AIDS-related Malignancies

NIH/NCI R01 CA66519-18

a) PI Dr. Shannon Kenney

b) 30 percent effort

c) 2/15/2008 through 1/31/2013

d) $164,698 direct costs current year

Molecular Biology and Genetics of Human Tumor Viruses

NIH Virology Program Project P01 CA022443-34

a) PI Dr. Bill Sugden

Project #4: Mechanisms of Reactivation of Epstein-Barr Virus from Latency to Lytic

Replication (Janet Mertz, Project Leader; Shannon Kenney, Co-Leader)

Project #5: Inhibiting the Survival and Proliferation of EBV-associated Tumor Cells (Shannon

Kenney, Project Leader; Janet Mertz and Bill Sugden, Co-Leaders)

b) 5 percent effort (Project 4); 15 percent effort (Project 5)

c) 6/25/2008 through 4/30/2013

d) $184,388 per year direct support

UWCCC Cancer Center Support Grant

NIH/NCI P30 CA014520-36

a) PI Dr. George Wilding

b) 5 percent effort

c) 4/1/2007 through 3/31/2013

d) None specifically for Dr. Kenney s research; Dr. Kenney is the Co-Leader of the program on

Human Cancer Virology

3

PUBLICATIONS

Refereed Journals:

1. Kenney, S., Natarajan, V., Strike, D., Khoury, G., and Salzman, N. JC virus enhancer-

promoter active in human brain cells. Science 226:1337-1339, 1984.

2. Santamaria, J., Kenney, S., and Stiles, A. Purpura Fulminans associated with Haemophilus

Influenza type B infection. North Carolina Medical Journal 46:516-517, 1985.

3. Kenney, S., Natarajan, V., Selzer, G., and Salzman, N. Mapping 5' termini of JCV Late

mRNA. J. Virology 58:216-219, 1986.

4. Kenney, S., Natarajan, V., Selzer, G., and Salzman, N. Mapping 5' termini of JCV early

mRNA. J. Virology 58:651-654, 1986.

5. Davis, M.G., Kenney, S., Kamine, J., Pagano, J.S., and Huang, E.S. A major Immediate-early

gene of human cytomegalovirus transactivates the promoter of human T-cell leukemia virus,

Type III. Proc. Natl. Acad. Sci. U.S.A. 84:8642-8646, 1987.

6. Kenney, S., Kamine, J., Markovitz, D., Fenrick, R., and Pagano, J. An EBV immediate-early

gene product transactivates gene expression from the Human Immunodeficiency Virus long

terminal repeat. Proc. Natl. Acad. Sci. U.S.A. 85:1652-1656, 1988.

7. Pagano, J., Kenney, S., Markovitz, D., and Kamine, J. Epstein-Barr Virus and Interactions

with Human Retroviruses. Journal of Virological Methods 21:229-239, 1988.

8. Kenney, S., Kamine, J., Holley-Guthrie, E., Lin, J.-C., Mar, E.C., and Pagano, J.S. The EBV

BZLF1 Immediate-early gene product differentially affects latent versus productive EBV

promoters. J. Virology 63:1729-1736, 1989.

9. Kenney, S., Kamine, J., Holley-Guthrie, E., Markovitz, D., and Pagano, J.S. The EBV

immediate-early gene product, BMLF1, transactivates by a post-transcriptional mechanism

which is reporter-gene dependent. J. Virology 63:3870-3877, 1989.

10. Kenney, S., Holley-Guthrie, E., and Mar, E.C. The EBV BMLF1 promoter contains an

enhancer element responsive to the BZLF1 and BRLF1 transactivators. J. Virology 63:3878-

3883, 1989.

11. Markovitz, D., Kenney, S., Kamine, J., Smith, M., Baber, B., Fenrick, R., Huang, E.-S., Rosen,

C., Haseltine, W., and Pagano, J.S. Disparate effects of two herpesvirus Immediate-early gene

trans-activators on the HIV-1 LTR. Virol. 173:750, 1989.

12. Quinlivan, E.B., Holley-Guthrie, E., Mar, E.-C., Smith, M. and Kenney, S.C. The EBV

BRLF1 immediate-early gene product transactivates the HIV1-LTR by a mechanism which is

enhancer-dependent. J. Virology 64:1817-1820, 1990.

13. Holley-Guthrie, E., Quinlivan, E.B., Mar, E.-C., and Kenney, S.C. The Epstein-Barr Virus

(EBV) is regulated by the EBV Transactivators, BRLF1 and BZLF1, in a cell-specific manner.

J. Virology 64:3753-3759, 1990.

14. Sung, N., Kenney, S., Gutsch, D., and Pagano, J. EBNA2 transactivates a lymphoid-specific

enhancer in the BAMHI-C promoter of the Epstein-Barr Virus. J. Virology 65:2164-2169,

1991.

15. Kenney, S.C., Holley-Guthrie, E., Gutsch, D., Bender, T., Giot, J. and Sergeant, A. The

cellular oncogene, c-myb, can interact synergistically with BZLF1 in lymphoid cells.

Molecular and Cellular Biology 12:136-146, 1992.

16. Shapiro, D., Kenney, S., Johnson, M., and Wyrick, P. Chlamydia Psittici Endocarditis

Diagnosed by Positive Culture from Blood. New England Journal of Medicine 326:1192-1195,

1992.

4

17. Quinlivan, E.B., Norris, M., Bouldin, T., Suzuki, K., Meeter, R., Smith, M., Hall, C., and

Kenney, S. Subclinical central nervous system infection with JC virus in patients with AIDS.

J. Infectious Diseases 166:80-85, 1992.

18. Zalani, S., Holley-Guthrie, E., Gutsch, D., and Kenney, S. The Epstein-Barr virus (EBV)

immediate-early promoter, BRLF1, can be activated by the cellular Sp1 transcription factor. J.

Virology 66:7282-7292, 1992.

19. Sista, N., Pagano, J., Liao, W., and Kenney, S. Retinoic acid is a negative regulator of the

Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl.

Acad. Sci. 90:3894-3898, 1993.

20. Quinlivan, E.B., Holley-Guthrie, E., Norris, M., Gutsch, D., Bachenheimer, S., and Kenney, S.

Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-

Barr virus early gene promoter, BMRF1. Nucleic Acids Research 21:1999-2007, 1993

(erratum NAR 21:3340).

21. Gutsch, D., Holley-Guthrie, E., Zhang, Q., Stein, B., Blanar, M., Baldwin, A., and Kenney, S.

The bZIP transactivator, BZLF1, of Epstein-Barr virus functionally and physically interacts

with the p65 subunit of NF-KB. Mol Cell. Biol. 14:1939-1948, 1994

22. Zhang, Q., Gutsch, D., and Kenney, S. Functional and physical interactions between p53 and

BZLF1: implications for Epstein-Barr virus latency. Molecular and Cellular Biology 14:1929-

1938, 1994.

23. Furnari, F., Quinlivan, E.B., Kenney, S., and Pagano, J. RAZ, an Epstein-Barr virus

transdominant repressor that modulates the viral reactivation mechanism. Journal of Virology

68:1827-1836, 1994.

24. Gutsch, D., Marcu, K., and Kenney, S. The Epstein-Barr virus BRLF1 gene product

transactivates the murine and human c-myc promoters. Cellular and Molecular Biology

40:747-760, 1994.

25. Kenney, S., and Pagano, J. Viruses as oncolytic agents: a new age for "therapeutic" viruses?

Journal of the National Cancer Institute 86:1185-1186, 1994.

26. Kenney, S. and Zalani, S. Regulation of BZLF1 function by viral and host cell factors.

Epstein-Barr Virus Report 2:23-28, 1995.

27. Zalani, S., Holley-Guthrie, E., and Kenney, S. The Zif268 cellular transcription factor

activates expression of the Epstein-Barr virus Immediate-early BRLF1 Promoter. Journal of

Virology 69:3816-3823, 1995.

28. Zhang, Q., Hong, H., Dorski, D., and Kenney, S. Functional and physical interactions between

the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and

lytic replication. J. Virology 70:5131-5142, 1996.

29. Zalani, S., Holley-Guthrie, E. and Kenney, S. Epstein-Barr viral latency is disrupted by the

Epstein-Barr virus Immediate-early BRLF1 through a cell-specific mechanism. Proc. Natl.

Acad. Sci. USA 93:9194-9199, 1996.

30. Rogers, R., Ge, J.-Q., Hoganson, D., Comstock, K., Olsen, J. and Kenney, S. Killing EBV-

positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and

HSV thymidine kinase. Human Gene Therapy 7:2235-2245, 1996.

31. Zalani, S., Coppage, A., Holley-Guthrie, E., and Kenney, S. The cellular YY1 transcription

factor binds a cis-acting negatively regulating element in the Epstein-Barr virus BRLF1

promoter. J. Virology 71:3268-3274, 1997.

32. Hong, H., Holley-Guthrie, E. and Kenney, S. The bZip dimerization domain of the Epstein-

Barr virus BZF1 protein mediates lymphoid-specific negative regulation. Virology 229:36-48,

1997.

5

33. Zhang, Q., Holley-Guthrie, E., Ge, J.-Q., Dorsky, D. and Kenney, S. The Epstein-Barr virus

(EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream

component of the EBV oriLyt. Virology 230:24-34, 1997.

34. Kenney, S., Ge, J.-Q., Westphal, E., and J. Olsen. Gene therapy strategies for treating EBV-

associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Human

Gene Therapy: 9:1131-1141, 1998.

35. Adamson, A., and Kenney, S. Rescue of the Epstein-Barr virus BZLF1 mutant, Z (S186A),

early gene activation defect by the BRLF1 gene product. Virology 251:187-197, 1998.

36. Zhang, Q., Holley-Guthrie, E., Dorsky, D., and Kenney, S. Identification of transactivator and

nuclear localization domains in the Epstein-Barr virus (EBV) DNA polymerase accessory

protein, BMRF1. Journal of General Virology 80:69-74, 1999.

37. Westphal, E.-M., Mauser, A., Swenson, J., Davis, M., Talarico, C., and Kenney, S. Induction

of lytic Epstein-Barr virus (EBV) infection in lymphomas using adenovirus vectors in vivo.

Cancer Research 59:1485-191, 1999.

38. Adamson, A., and Kenney, S. The Epstein-Barr virus BZLF1 protein interacts physically and

functionally with the Histone Acetylase CREB-binding protein. J. Virology 73:6551-6558,

1999.

39. Swenson, J., Mauser, A., Kaufman, W., and Kenney, S. The Epstein-Barr virus protein

BRLF1 activates S phase entry through E2F1 induction. J. Virology 73:6540-6550, 1999.

40. Westphal, E. M., Ge, J.-Q., and Kenney, S. The CB1954/nitroreductase combination in EBV-

positive B cell lines: induction of bystander killing in vitro and in vivo. Cancer Gene Therapy

7:97-106, 2000.

41. Adamson, A., Darr, D., Holley-Guthrie, E., Johnson, R., Mauser, A., Swenson, J. and Kenney,

S. Epstein-Barr virus immediate-early proteins, BZLF1 and BRLF1, activate the ATF2

transcription factor by increasing the levels of phosphorylated p38 and c-jun N-terminal

kinases. J. Virology 74:1224-1233, 2000.

42. Westphal, E., Blackstock, W., Feng, W., Israel, B., and Kenney, S. Activation of lytic Epstein-

Barr virus infection by radiation and sodium butyrate in vitro and in vivo: a potential method

for treating EBV-positive malignancies. Cancer Research 60:5781-5788, 2000.

43. Adamson, A., and Kenney, S. The Epstein-Barr virus immediate-early protein BZLF1 is

Sumo-1 modified and disrupts promyelocytic leukemia (PML) bodies. Journal of Virology

75:2388-2399, 2001.

44. Swenson, J., Holley-Guthrie, E., and Kenney, S. The Epstein-Barr virus immediate-early

protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. Journal of

Virology 75: 6228-6234, 2001.

45. Israel, B., Pickles, R., Segal, D., Gerard, R., and Kenney, S. Enhancement of adenoviral vector

entry into CD70-positive B cell lines using Bi-specific CD70/adenovirus fiber antibody.

Journal of Virology 75: 5215-5221, 2001.

46. Darr, D., Mauser, A., and Kenney, S. The Epstein-Barr virus immediate-early protein, BRLF1,

induces the lytic form of viral replication through a mechanism involving phosphatidylinositol

3 (PI3) kinase activation. Journal of Virology 75: 6135-6142, 2001.

Morrison E, Mauser A, Wong A, Ting J, and Kenney, S. Inhibition of IFN- -signaling by an

47.

Epstein-Barr virus immediate-early protein. Immunity. 15: 787-99, 2001.

48. Feng W., Israel B., Raab-Traub N., Busson P., Kenney, S. Chemotherapy Induces Lytic EBV

Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors.

Cancer Research. 62: 1920-1926, 2002.

6

49. Mauser A, Shin ichi S, Ettore A, Anderson CW, and Kenney, S. The Epstein-Barr Virus

Immediate-Early Protein, BZLF1, Regulates p53 Function Through Multiple Mechanisms.

Journal of Virology. 76:125**-*****, 2002.

50. Mauser A, Holley-Guthrie E, Simpson D, Kaufmann W, and Kenney, S. The Epstein-Barr

Virus Immediate-Early Protein, BZLF1, Induces Both A G2 and Mitotic Block. Journal of

Virology. 76: 100**-*****, 2002.

51. Feng, W. Westphal, E., Raab-Traub, N., Gulley, ML, Busson, P., and Kenney, S. The use of

Adenovirus Vectors Expressing the Epstein-Barr Virus (EBV) Immediate-Early Proteins

BZLF1 and BRLF1 to Treat EBV-Positive Tumors. Journal of Virology 76:109**-*****,

2002.

52. Mauser, A., Holley-Guthrie, E., Zanation, A., Yarborough, W., Kaufmann, W., Klingelhutz, A.,

and Kenney, S. The Epstein-Barr virus immediate-early protein, BZLF1, induces expression

of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and

gastric carcinoma cells. Journal of Virology 76:125**-*****, 2002.

53. Israel, B. and Kenney, S. Virally targeted therapies for EBV-associated malignancies.

Oncogene 22:5122-5130, 2003.

54. Morrison, T., Mauser, A., Klingelhutz, A., and Kenney, S. The Epstein-Barr Virus Immediate-

Early Protein BZLF1 Inhibits Tumor Necrosis Factor- Induced Signaling and Apoptosis By

Downregulating Tumor Necrosis Factor Receptor-1. Journal of Virology 78:544-549, 2004.

55. Feng W., Hong, G., Delecluse, H.-J., and Kenney, S. Lytic induction therapy for Epstein-Barr

virus-positive B-cell lymphomas. Journal of Virology 78:1893-1902, 2004.

56. Li, Y., Webster-Cyriaque, Tomlinson, C., Yohe, M., and Kenney, S. Fatty acid synthase

expression is induced by the Epstein-Barr virus immediate-early protein, BRLF1, and is

required for lytic viral gene expression. Journal of Virology 78:4197-4206, 2004.

57. Hong, G., Delecluse, H.-J., Gruffat, H., Morrison, T., Feng, W., Kenney, S. The BRRF1 early

gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic

infection by BRLF1. Journal of Virology 78:4983-4992, 2004.

58. Morrrison, T. and Kenney, S. BZLF1, an Epstein-Barr virus immediate-early protein, induces

p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 328:219-232,

2004.

59. Li, Y., Mahajan, N., Webster-Cyriaque, J., Bhende, P., Earp, H.S., and Kenney, S. C-Mer is

induced by the Epstein-Barr virus immediate-early protein BRLF1. Journal of Virology

78:117**-*****, 2004.

60. Makhov, A., Subramanian, D., Holley-Guthrie, E., Kenney, S.C., and Griffith, J. The Epstein-

Barr virus polymerase accessory factor, BMRF1, adopts a ring shaped structure as visualized

by electron microscopy. Journal of Biological Chemistry 279:403**-*****, 2004.

61. Feng, W., Cohen, J., Fischer, J., Li, L., Sneller, M., Goldbach-Mansky, R., Raab-Traub, N.,

Delecluse, H.-J., and Kenney, S. Methotrexate induces reactivation of latent Epstein-Barr

virus: a potential contributor to methotrexate-associated lymphomas. Journal of the National

Cancer Institute 96:1691-1702, 2004.

62. Bhende, P., Seaman, W., Delecluse, H.-J., and Kenney, S. The EBV lytic switch protein, Z,

activates the methylated viral genome through a novel mechanism. Nature Genetics 36:1099-

1104, 2004.

63. Holley-Guthrie, E., Seaman, W., Bhende, P., Merchant, J., and Kenney, S.C. The Epstein-Barr

virus protein, BMRF1, activates gastrin transcription. Journal of Virology 79:745-55, 2005.

64. Bhende, P., Seaman, T., Delecluse, H.-J., and Kenney, S. BZLF1 activation of the methylated

form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. Journal of

Virology 79:7338-7348, 2005.

7

65. Hong, G., Gulley, M., Feng, W.-H., Delecluse, H.-J., Holley-Guthrie, E., and Kenney, S.

Epstein-Barr virus lytic infection contributes to tumorigenesis in a SCID mouse model of

lymphoma. Journal of Virology 79: 13993-4003, 2005.

66. Hong, G., Kumar, P., Wang, L., Damania, B., Gulley, M., Delecluse, H.-J., Polverini, P., and

Kenney, S. Epstein-Barr virus lytic infection is required for efficient production of the

angiogenesis factor VEGF in lymphoblastoid cell lines. Journal of Virology 79: 139**-*****,

2005.

67. Israel, B., Feng, W.H., Gulley, P., and Kenney, S. Anti-CD70 antibodies: a potential treatment

for EBV-positive CD70-expressing lymphomas. Molecular Cancer Therapeutics 4: 2037-44,

2005.

68. Gonzalez, C.M., Wong, E., Bowser, B., Hong, G., Kenney, S., and Damania, B. Identification

and characterization of the KSHV ORF49 protein. Journal of Virology 80:3062-70, 2006.

69. Kenney, S. Development of Novel, EBV-targeted therapies for EBV-positive tumors.

Transactions of the American Clinical and Climatological Association 117: 55-73, 2006.

70. Feng, W., and Kenney, S. Valproic acid enhances the efficacy of chemotherapy in EBV-

positive tumors by increasing lytic viral gene expression. Cancer Research 66:8762-8769,

2006.

71. Bhende, P. M., Dickerson, S. J., Sun, X., Feng, W. H., and Kenney, S. C. X-box binding

protein 1 (XBP-1) activates lytic Epstein-Barr virus gene expression in combination with

protein kinase D (PKD). Journal of Virology 81:7363-73-70, 2007.

72. Jones, R., Bhende, P., Jones, D., Delecluse, H. J., and Kenney, S. Epstein-Barr virus infection

induces retinoic acid-responsive genes through induction of a retinol metabolizing enzyme,

DHRS9. Journal of Biol. Chem. 282:8317-24, 2007.

73. Jones, RJ, Seaman, WT, Feng, WH, Barlow, E., Dickerson, S., Delecluse, H.J., and Kenney,

SC. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell

lines and EBV-related lymphoproliferative disease. International Journal of Cancer 121:1274-

1281, 2007.

74. Feng, W.-H., Kraus, R. J., Dickerson, S. J., Lim, H. J., Jones, R. J., Yu, X., Mertz, J. E., and

Kenney, S. C. ZEB1 and c-Jun Levels Contribute to the Establishment of Highly Lytic

Epstein-Barr Virus Infection in Gastric AGS Cells. J. Virol. 81: 101**-*****, 2007.

75. Yu, F., Feng, J., Harada, J. N., Chanda, S. K., Kenney, S. C., and Sun, R. B Cell Terminal

Differentiation Factor XBP-1 Induces Reactivation of Kaposi s Sarcoma-Associated

Herpesvirus. FEBS Lett. 581: 3485-3488, 2007.

Bristol, J. A., Morrison, T. E., and Kenney, S. C. CCAAT/Enhancer Binding Proteins and

76.

Regulate the Tumor Necrosis Factor Receptor 1 Gene Promoter. Mol. Immunol. 46: 2706-

2713, 2009. PMCID: PMC2724677.

77. Dickerson, S. J., Xing, Y., Robinson, A. R., Seaman, W. T., Gruffat, H., and Kenney, S. C.

Methylation-Dependent Binding of the Epstein-Barr Virus BZLF1 Protein to Viral Promoters.

PLoS Pathog. 5(3):e1000356, 2009. PMCID: PMC2654727.

78. Ryan, J. L., Jones, R. J., Elmore, S. H., Kenney, S. C., Miller, G., Schroeder, J. C., and Gulley,

M. L. Epstein-Barr Virus WZhet DNA Can Induce Lytic Replication in Epithelial Cells in

vitro, although WZhet Is Not Detectable in Many Human Tissues in vivo. Intervirology 52: 8-

16, 2009. PMCID: PMC2865398.

79. Ryan, J., Shen, Y., Morgan, D., Elmore, S., Thorne, L., Dominguez, R., Kenney, S., and

Gulley, M. Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.

Intervirology. 2009;52(1):8-16. Epub 2009 Apr 7.

8

80.. Bristol, J. A., Robinson, A. R., Barlow, E. A., and Kenney, S. C. The Epstein-Barr Virus

BZLF1 Protein Inhibits Tumor Necrosis Factor Receptor 1 Expression through Effects on

Cellular C/EBP Proteins. J. Virol., 84: 123**-*****, 2010. PMCID: PMC2976414.

81. Hagemeier, S. R., Dickerson, S. J., Meng, Q., Yu, X., Mertz, J. E., and Kenney, S. C.

Sumoylation of the Epstein-Barr Virus BZLF1 Protein Inhibits Its Transcriptional Activity and

Is Regulated by the Virus-Encoded Protein Kinase. J. Virol., 84: 4383-4394, 2010. PMCID:

PMC2863741.

82. Meng, Q., Hagemeier, S. R., Kuny, C. V., Kalejta, R. F., and Kenney, S. C. Simian Virus 40

T/t Antigens and Lamin A/C Small Interfering RNA Rescue the Phenotype of an Epstein-Barr

Virus Protein Kinase (BGLF4) Mutant. J. Virol., 84: 4524-4533, 2010. PMCID:

PMC2863785.

83. Meng, Q., Hagemeier, S. R., Fingeroth, J. D., Gershburg, E., Pagano, J. S., and Kenney, S. C.

The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine

Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral

Production. J. Virol., 84: 4534-4542, 2010. PMCID: PMC2863746.

84. Ryan, J. L., Jones, R. J., Kenney, S. C., Rivenbark, A. G., Tang, W., Knight, E. R. W.,

Coleman, W. B., and Gulley, M. L. Epstein-Barr Virus-Specific Methylation of Human Genes

in Gastric Cancer Cells. Infect. Agents Cancer, 5:27, 2010. PMCID: PMC3023757.

85. Sun, X., and Kenney, S. C. Hsp90 Inhibitors: A Potential Treatment for Latent EBV

Infection? Cell Cycle, 9: 1665-1666, 2010. PMCID: PMC2879875.

86. Sun, X., Barlow, E. A., Ma, S., Hagemeier, S. R., Duellman, S. J., Burgess, R. R., Tellam, J.,

Khanna, R., and Kenney, S. C. Hsp90 Inhibitors Block Outgrowth of EBV-Infected Malignant

Cells in vitro and in vivo through an EBNA1-Dependent Mechanism. Proc. Natl. Acad. Sci.

USA, 107: 3146-3151, 2010. PMCID: PMC2840277.

87. Tang, W., Harmon, P., Gulley, M. L., Mwansambo, C., Kazembe, P. N., Martinson, F.,

Wokocha, C., Kenney, S. C., Hoffman, I., Sigel, C., Maygarden, S., Hoffman, M., and Shores,

C. Viral Response to Chemotherapy in Endemic Burkitt Lymphoma. Clin. Cancer Res., 16:

2055-2064, 2010. PMCID: PMC2848899.

88. Hagemeier, S. R., Barlow, E. A., Kleman, A. A., and Kenney, S. C. The Epstein-Barr Virus

BRRF1 Protein, Na, Induces Lytic Infection in a TRAF2- and p53-Dependent Manner. J.

Virol., 85: 4318-4329, 2011. PMCID: PMC3126225.

89. Hegde, S., Lockridge, J. L., Becker, Y. A., Ma, S., Kenney, S. C., and Gumperz, J. E. Human

NKT Cells Direct the Differentiation of Myeloid APCs That Regulate T Cell Responses via

Expression of Programmed Cell Death Ligands. J. Autoimmun., 37: 28-38, 2011. PMCID:

PMC3110565.

90. Ma, S.-D., Hegde, S., Young, K. H., Sullivan, R., Rajesh, D., Zhou, Y., Jankowska-Gan, E.,

Burlingham, W. J., Sun, X., Gulley, M. L., Tang, W., Gumperz, J. E., and Kenney, S. C. A

New Model of Epstein-Barr Virus Infection Reveals an Important Role for Early Lytic Viral

Protein Expression in the Development of Lymphomas. J. Virol., 85: 165-177, 2011. PMCID:

PMC3014199.

91. Robinson, A. R., Kwek, S. S., Hagemeier, S. R., Wille, C. K., and Kenney, S. C. Cellular

Transcription Factor Oct-1 Interacts with the Epstein-Barr Virus BRLF1 Protein To Promote

Disruption of Viral Latency. J. Virol., 85: 8940-8953, 2011. PMCID: PMC3165789.

92. Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., Dotti, G., Wu,

M.-F., Liu, H., Kenney, S., and Gottschalk, S. T Cells Redirected Against CD70 for the

Immunotherapy of CD70-Positive Malignancies. Blood, 117: 4304-4314, 2011. PMCID:

PMC3087480.

9

93. Robinson, A. R., Kwek, S. S., and Kenney, S. C. The B-Cell Specific Transcription Factor,

Oct-2, Promotes Epstein-Barr Virus Latency by Inhibiting the Viral Immediate-Early Protein,

BZLF1. PLoS Pathog., 8(2):e1002516, 2012. PMCID: PMC Journal In Process.

94. Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, Dominguez RL, Gulley ML: Epstein-

Barr virus infection is common in inflamed gastrointestinal mucosa. Digestive Diseases and

Sciences, in press.

Invited Papers Published in Conference Proceedings:

1. Kenney, S., Lin, J.C., and Pagano, J.S. Transactivation of an EBV promoter within the IR-1

region of the genome. In: Epstein-Barr Virus and Human Disease (Ablashi,D., Faggioni, A.,

Nonoyama, M., Pearson, G.R., and Glaser, R., eds.). Humana Press, Clifton, New Jersey. pp.

25-30, 1987.

2. Kenney, S., Kamine, J., Holley-Guthrie, E., and Lin, J. Effect of the BZLF1 Transactivator on

Different Classes of EBV Promoters. In: Epstein-Barr Virus and Human Disease, (Ablashi, D.,

Faggioni, G., Krueger, G., Pagano, J., and Pearson, G., eds.). Humana Press, Clifton, New

Jersey, pp. 55-60, 1989.

3. Lin, J.-C., Kenney, S., and Pagano, J.S. Detection of proteins binding to the EBNA 2

promoter. In: Epstein-Barr Virus and Human Diseases, (Ablashi, D., Faggioni, G., Krueger,

G., Pagano, J.,. and Glaser, R., eds). Humana Press, Clifton, New Jersey, pp. 105-112, 1989.

4. Kenney, S., Holley-Guthrie, E., Gutsch, D., Giot, J., and Sergeant, A. The EBV BRLF1

protein has sequence and functional similarity with the c-myb proto-oncogene. In: Epstein-

Barr Virus and Human Disease (Ablashi, D., Huang, A., Pagano, J., Pearson, G., and Yang, C.,

eds.). Humana press, Clifton, New Jersey, pp. 93-97, 1991.

5. Sung, N., Kenney, S., and Pagano, J. A new lymphoid specific EBV enhancer is transactivated

by EBNA-2. In: Epstein-Barr Virus and Human Disease, (Ablashi, D., Huang, A., Pagano, J.,

Pearson, G., and Yang, C., eds.). Humana Press, Clifton, New Jersey, pp. 53-57, 1991.

6. Kenney, S., Zalani, S, Zhang, Q., Gutsch, D., and Holley-Guthrie, E. The regulation of the Z

transactivator function by cellular proteins. In: Epstein-Barr virus and Human Disease

(Ablashi, D., Huang, A., Pagano, J., Pearson, G., and Yang, C., eds.). Humana press, Clifton,

New Jersey. 1993.

7. Sista, N., Kenney, S., Liao, W., and Pagano, J. Retinoic acid is a negative regulator of BZLF1-

mediated gene expression. In: Epstein-Barr Virus and Human Disease (Ablashi, D., Huang,

A., Pagano, J., Pearson, G., and Yang, C., eds.). Humana Press, Clifton, New Jersey. 1993.

Book Chapters:

1. Raab-Traub, N. and Kenney, S. Epstein-Barr virus: Pathogenesis and treatment. In: Viral

Infections and Treatment (Marcel Dekker Publishing, New York), 2002.

2. Israel, B. and Kenney, S.C. Infectious Mononucleosis. In: Netter s Internal Medicine, Edited

by M. Runge and M.A. Greganti (Icon Learning Systems, Teterboro, New Jersey), 2003.

3. Israel, B. and Kenney, SC. EBV lytic Infection. In: Epstein-Barr Virus, Edited by Erle S.

Robertson, Caister Academic Press, 2005.

4. Kenney, S. C. Reactivation and Lytic Replication of EBV. In: A. Arvin, G. Campadelli-

Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, and K. Yamanishi (Eds.), Human

10

5. Swaminathan, S and Kenney, S. The Epstein-Barr Virus Lytic Epstein-Barr virus infection.

In: DNA Tumor Viruses, Damania, B. and Pipas, eds., Springer Science/Business Media, NY,

2009.

Invited Research Presentations (since 2005):

1. June 2005: Invited speaker at the International Symposium on Nasopharyngeal Carcinoma,

Toronto, Canada

2. October, 2005: Invited seminar speaker, Baylor University, Houston, TX

3. October 2005: Invited speaker, American Clinical and Climatological Association meeting,

Santa Barbara, CA

4. January, 2006: Invited speaker, University of Wisconsin-Madison

5. February 2006: Invited speaker, University of Michigan-Ann Arbor

6. April 2006: Invited speaker, First International Conference on Viral Oncogenes, Padova, Italy

7. May 2006: Invited speaker, Duke University

8. July 2006: Keynote speaker, International Epstein-Barr virus Meeting, Boston, MA

9. November 2006: Seminar speaker, Institute for Molecular Virology, University of Wisconsin

10. February 2007: Seminar speaker, Microbiology and Immunology Department, University of

Wisconsin

11. May 2007: Seminar speaker, Department of Pathology, University of Wisconsin

12. June 2007: Grand Rounds speaker, Department of Medicine, University of Wisconsin

13. April 2007: Invited keynote speaker, President s Symposium, at American Society for

Investigative Pathology, Washington, D.C.

14. July 2007: Invited speaker, International Herpesvirus workshop, Asheville, NC

15. March 2008: Invited Speaker, Department of Microbiology, Rosalyn Franklin Medical School

16. April 2009: Invited Speaker, University of San Antonio, TX, Cancer Center

17. October 2010: Invited Speaker, NIH AIDS Malignancy Consortium

18. October 2010: Invited Speaker, Grand Rounds, UWCC

19. October 2010: Invited Speaker, Grand Rounds, UW Human Biology Department

20. November 2010: Invited Speaker, Department of Microbiology, Northwestern Medical School

21. May 2011: Invited Speaker, Virology Training Program, Johns Hopkins Cancer Center

22. May 2012: Invited Speaker, Ohio State University Cancer Center, May 2012

23. Feb 2013: Invited Speaker, University of Utah Cancer Center

SELECTED ADMINISTRATIVE ACTIVITIES

At UNC-Chapel Hill:

Member, Lineberger Comprehensive Cancer Center Tissue Culture Facility Committee

Member, Sarah G. Kenan Professorship Selection Committee

Member, UNC Gene Therapy Trials Review Committee

Admissions Committee, UNC M.D./PH.D. Program

Member, UNC School of Medicine Tenure Review Committee (To Associate Professor)

Member, Department of Medicine Research Advisory Committee

At University of Wisconsin:

11

1. Co-program leader of Virology Program, Comprehensive Cancer Center

2. Member, Committee to suggest future goals for Infectious Diseases Division

3. Member, Committee to hire/recruit new faculty members for Oncology Department

4. Member of multiple PhD thesis committees

5. Former member of U.W. Medical School Promotion committee

6. Member of CTSA K award committee

7. Member of U.W. Medical School Award Committee

National Service:

1. Former permanent member of NIH Study section, and frequent member of Special emphasis NIH

Study Sections

2. Board Member, International Epstein-Barr Virus Association, 2005-2010

3. Member, Burroughs Wellcome Fund s Scientific Advisory Committee for the Clinical Scientists

Awards in Translational Research, 2005-present.

4. Member of the Editorial Board, Journal of Virology

Clinical Activities (UNC-Chapel Hill and University of Wisconsin):

Infectious Diseases Consult attending (1 to 2 months per year in Wisconsin starting in Sept. 2007)

12

Contact this candidate